Business Context and Reporting Period
This Form 8-K is a current report filed by Neuralstem, Inc. (not Palisade Bio, Inc., as indicated in the metadata) on June 20, 2012, covering events occurring on June 19, 2012. The filing details the results of the Company's 2012 Annual Meeting of Stockholders and a significant clinical milestone in its ongoing Phase I trial for amyotrophic lateral sclerosis (ALS).
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and clinical developments rather than financial performance.
Material Changes and Corporate Actions
- Annual Meeting Results: On June 19, 2012, the Company held its Annual Meeting. As of the record date (May 11, 2012), 54,095,105 shares were outstanding, with 44,868,289 shares represented at the meeting, constituting a quorum.
- Director Election: Scott V. Ogilvie was elected as the Class I Director nominee. He received 9,859,631 votes for, 133,009 votes withheld, and 34,875,649 non-votes.
- Auditor Ratification: Stockholders ratified Stegman & Company as the independent registered public accounting firm for the fiscal year ending December 31, 2012. The vote was 44,716,872 for, 86,028 against, and 65,389 abstentions.
Outlook, Management Commentary, and Clinical Updates
Under Item 8.01 (Other Events), the Company announced a major clinical milestone: the first patient to receive stem cell transplantation in both regions of the spinal cord has been treated in the ongoing Phase I trial of its spinal cord neural stem cells for ALS (Lou Gehrig's disease). This development is highlighted as a significant step in the Company's therapeutic program.
Key Facts for Investor Verification
- Verify the clinical status and safety data of the Phase I ALS trial following the dual-region transplantation.
- Confirm the tenure and responsibilities of the newly elected Class I Director, Scott V. Ogilvie.
- Review the attached press release (Exhibit 99.01) for detailed information regarding the ALS trial patient treatment.
- Note that this filing contains no financial data; investors should refer to the most recent 10-K or 10-Q for financial health indicators.